Genovate Biotechnology Co Ltd (4130) — Cash Flow Quality Index
Genovate Biotechnology Co Ltd (4130) has a Cash Flow Quality Index of -3.61x as of June 2025. Operating cash flow of NT$-26.50 Million is below net income of NT$7.34 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore 4130 cash flow metrics to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Genovate Biotechnology Co Ltd Cash Flow Quality Index (2015–2025)
Historical Cash Flow Quality Index for Genovate Biotechnology Co Ltd across 10 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check total reinvestment intensity of Genovate Biotechnology Co Ltd to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Genovate Biotechnology Co Ltd (2015–2025)
Year-by-year earnings quality comparison for Genovate Biotechnology Co Ltd. For live market cap and the full company financial profile, see Genovate Biotechnology Co Ltd (4130) market capitalisation.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 3.75x | NT$43.79 Million | NT$11.68 Million | ▲ +74.8% |
| 2024 | 2.14x | NT$55.11 Million | NT$25.70 Million | ▼ -25.8% |
| 2023 | 2.89x | NT$84.78 Million | NT$29.33 Million | ▲ +106.2% |
| 2021 | -46.40x | NT$-17.26 Million | NT$372.00K | ▼ -2163.6% |
| 2020 | 2.25x | NT$87.08 Million | NT$38.73 Million | ▲ +72.3% |
| 2019 | 1.30x | NT$44.43 Million | NT$34.05 Million | ▲ +20.0% |
| 2018 | 1.09x | NT$62.88 Million | NT$57.85 Million | ▲ +417.8% |
| 2017 | 0.21x | NT$31.27 Million | NT$148.97 Million | ▼ -88.3% |
| 2016 | 1.80x | NT$70.58 Million | NT$39.21 Million | ▲ +157.3% |
| 2015 | 0.70x | NT$32.53 Million | NT$46.49 Million | — |